Phase 3 Clinical Trials With Primary Completion Dates in November 2018
This is a list of Phase 3 trials with primary completion dates in November 2018 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|ALKS||Alkermes plc||2018-11-01||Phase 3||NCT02694328||A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)|
|BYSI||BeyondSpring, Inc.||2018-11-01||Phase 3||NCT02504489||Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC|
|CPRX||Catalyst Pharmaceuticals, Inc.||2018-11-01||Phase 3||NCT02562066||Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes|
|ICLR||ICON plc||2018-11-01||Phase 3||NCT02794168||Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury|
|IMGN||ImmunoGen, Inc.||2018-11-01||Phase 3||NCT02631876||PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer|
|PRAH||PRA Health Sciences, Inc.||2018-11-01||Phase 3||NCT02817841||E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - US/CA Study|
|RDHL||Redhill Biopharma Ltd.||2018-11-01||Phase 3||NCT03198507||ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator|
|VBIV||VBI Vaccines, Inc.||2018-11-01||Phase 3||NCT03408730||Lot-to-lot Consistency of Sci-B-Vacâ¢ in Adults|
|VSTM||Verastem, Inc.||2018-11-01||Phase 3||NCT02049515||A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07|